EYE » Topics » Refractive sales rose 55.5% to $120.5 million. Pro forma refractive sales rose 3.1%.
This excerpt taken from the EYE 8-K filed May 1, 2008.
Refractive sales rose 55.5% to
$120.5 million. Pro forma refractive sales rose 3.1%.
Procedures, implants and related sales rose 46% to $85.4 million, or 3.9% on a pro forma basis as softness in the U.S. excimer and refractive IOL market was offset
by increased global penetration of the companys IntraLase technology, and international growth of all its refractive procedures and implants.
AMOs U.S. excimer procedure volumes declined approximately 10% in the first quarter and were virtually unchanged for the trailing 12 months ended
March 28, 2008. For the trailing 12 months ended March 28, 2008, the companys U.S. custom mix was 66%; the first-quarter custom mix was 69%, compared to 64% in the year-ago quarter.
AMOs U.S. femtosecond procedure volumes rose approximately 16% in the first quarter and 29.8% for the trailing 12 months ended March 28, 2008, on a pro
AMOs international procedure, implant and related sales were $27.8 million, up 200%, or 48.5% on a pro forma basis.
System sales rose 158.1%, or 19.4% on a pro forma basis, to $26.8 million. Unit placements of the VISX® Star S4IR® excimer laser rose 10.0%. IntraLase® FS laser placements rose 35.4% on a pro forma basis. The increases reflect continued demand for the companys dual platform worldwide.
Bet you've never seen portfolio analytics like these.